1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Latvia Pharmaceuticals and Healthcare Report Q4 2016

Latvia Pharmaceuticals and Healthcare Report Q4 2016

  • August 2016
  • -
  • Business Monitor International
  • -
  • 79 pages

Includes 3 FREE quarterly updates



BMI View: Latvia's pharmaceutical and healthcare markets will be shaped by the country's ongoing fiscalausterity measures. Already severely underfunded, the healthcare sector is facing additional cuts which areproving highly unpopular with the public. Conversely, the pharmaceutical sector will experience significantgrowth in 2016, due to price increases rather than rising consumption. This will likely result in increasedcost-containment initiatives, repressing patented medicine growth in the longer term.

Headline Expenditure Projections

- Pharmaceuticals: EUR425mn (USD463mn) in 2015 to EUR476mn (USD523mn) in 2016; +11.9% inlocal currency terms and 13.0% in US dollar terms. Forecast upgraded from previous quarter.

- Healthcare: EUR1.03n (USD1.12bn) in 2015 to EUR1.07bn (USD1.18bn) in 2016; +4.3% in localcurrency terms and 5.3% in US dollar terms. Forecast upgraded from previous quarter.

Table Of Contents

Latvia Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Latvia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Latvia 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Latvia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Latvia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Latvia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Latvia 2012-2020) 24
OTC Drug Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Latvia 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Latvia 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Latvia 2014-2020) 29
Pharmaceuticals and Healthcare Risk/Reward Index 30
Central And Eastern Europe Risk/Reward Index - Q4 2016 30
Latvia Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Intellectual Property Issues 41
Pricing Regime 42
Reimbursement Regime 43
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Latvia 2010-2015) 48
Table: Healthcare Personnel (Latvia 2010-2015) 49
Table: Healthcare Activity (Latvia 2010-2015) 49
Research and Development 50
Clinical Trials 52
Epidemiology 53
Competitive Landscape 56
Research-Based Industry 56
Table: Multinational Market Activity 57
Generic Drugmakers 58
Pharmaceutical Distribution 58
Pharmaceutical Retail Sector 59
Company Profile 61
Grindeks 61
Olainfarm 65
Demographic Forecast 68
Table: Population Headline Indicators (Latvia 1990-2025) 69
Table: Key Population Ratios (Latvia 1990-2025) 69
Table: Urban/Rural Population and Life Expectancy (Latvia 1990-2025) 70
Table: Population By Age Group (Latvia 1990-2025) 70
Table: Population By Age Group % (Latvia 1990-2025) 71
Glossary 73
Methodology 75
Pharmaceutical Expenditure Forecast Model 75
Healthcare Expenditure Forecast Model 75
Notes On Methodology 76
Risk/Reward Index Methodology 77
Index Overview 78
Table: Pharmaceutical Risk/Reward Index Indicators 78
Indicator Weightings 79

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.